Title: Scientist
Company: Boehringer Ingelheim International GmbH
Location: Danbury, Connecticut, United States
Miranda L. Carpenter, Scientist III at Boehringer Ingelheim International GmbH, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in Immuno-Oncology and Biotechnology.
Ms. Carpenter has established herself as a leading expert in advancing cancer research and patient care. For the past decade, she has served as a scientist III at Boehringer Ingelheim International GmbH, a leading pharmaceutical manufacturer headquartered in Germany, where her responsibilities include proposing novel therapeutic targets, designing bispecific molecules, implementing strategic research plans, and evaluating the efficacy of large protein therapeutics. Ms. Carpenter’s expertise extends to testing molecule feasibility, assessing receptor binding and analyzing downstream cell signaling pathways.
Throughout her tenure, Ms. Carpenter’s work has been instrumental in developing a bispecific antibody that links T cells to fibroblasts, modulating immune responses for tumor treatment. Over a four-year project, she led feasibility studies, cytotoxicity assays and experimental design, culminating in an investigational new drug filing with the U.S. Food and Drug Administration and the initiation of first-in-human clinical trials in 2021. This achievement stands among Ms. Carpenter’s proudest professional milestones.
Before joining Boehringer Ingelheim International GmbH in 2016, Ms. Carpenter contributed her talents to Gen-Probe, later known as Hologic, Inc., and subsequently Hologic Immucor, in Stamford, Connecticut, between 2011 and 2016. The company specializes in antibody-DNA test kits for transplant diagnostics. In this matrix research and development environment, she performed good laboratory practice laboratory work and good manufacturing practice quality control while contributing to U.S. Food and Drug Administration investigational new drug filings. Ms. Carpenter played a key role in designing components for LIFECODES HLA SSO typing kits, focusing on primers and probes used to assess primary histocompatibility complex Class I and Class II phenotypes for organ acceptance or rejection. Her tenure ended after four years due to company downsizing and her decision not to relocate.
Ms. Carpenter’s academic foundation is rooted in rigorous scientific training. She holds a Bachelor of Science in biology from an accredited institution, completed in 2008. She then acquired a Master of Public Health in environmental health science from New York Medical College in Valhalla, New York, in 2010. Ms. Carpenter’s pursuit of graduate studies was inspired by an open house presentation by Dr. Diane Hack on chemical warfare and carcinogenesis, which led her to enroll at New York Medical College. Under Dr. Hack’s mentorship, she was awarded a U.S. Department of Defense project in collaboration with Rutgers University to develop countermeasures against chemical threats such as nitrogen mustard and sulfur mustard. Ms. Carpenter’s research examined the effects of protease inhibitors and MMP isoforms on desiccant injury.
From there, Ms. Carpenter completed three years of doctoral coursework in biochemistry and molecular biology. Although she left the doctoral program due to funding constraints, she gained valuable knowledge that continues to inform her research endeavors. Before studying the sciences, Ms. Carpenter graduated from the American Academy McAllister Institute of Funeral Service and became a licensed funeral director in 2001.
Ms. Carpenter’s professional credentials are complemented by active membership in the Society of Toxicology, reflecting her engagement with ongoing developments in toxicological sciences. She is also dedicated to fostering future generations of scientists through volunteer work with STEM programs.
As a seasoned researcher, Ms. Carpenter has made scholarly contributions, including co-authoring several peer-reviewed publications on topics such as nutrigenomics coupling, chronic diseases and obesity. Her works have been published in journals such as the Global Journal of Obesity, Diabetes and Metabolic Syndrome and in such books as “Emerging Trends in Disease and Health Research Vol. 3.” Ms. Carpenter has also presented posters at major conferences starting in 2009, including the Society of Toxicology, the American Public Health Association and the New York Medical College on topics related to endocrine disruptors such as bisphenol-A.
Ms. Carpenter’s achievements have been recognized with several honors, including an Achievement Award for milestone startup development from Boehringer Ingelheim International GmbH in 2022. She attributes her success to her passion for patient care and inspiration drawn from advances in cancer research. Deeply affected by high mortality rates associated with cancer, Ms. Carpenter remains committed to making meaningful contributions through groundbreaking developments within her field.
Looking ahead, Ms. Carpenter aims to deepen her expertise in immuno-oncology by focusing on breakthroughs that advance personalized medicine and meaningfully advance progress in cancer therapeutics. Notably, she intends to adopt a highly focused strategic framework to enhance her impact and contribute meaningfully to the development of personalized medicine.
For more information, please visit:
Contact Ms. Carpenter:
